AIMS: Cyclophilin A (CyPA) represents a ubiquitous intracellular protein, which is secreted by inflammatory and by dying/necrotic cells. The aim of this study was to evaluate the prognostic relevance of CyPA expression in endomyocardial biopsies of consecutive patients with congestive heart failure. METHODS AND RESULTS: A total of 227 unselected patients (age 53.9 ± 15 years) with congestive heart failure undergoing endomyocardial biopsy for diagnostic reasons were enrolled. Biopsies were analysed using established histopathological and immunohistological criteria together with CyPA staining. Virus genome was studied by polymerase chain reaction. CyPA was significantly enhanced in patients with inflammatory cardiomyopathy (n = 127) as compared with patients with non-inflammatory cardiomyopathy (n = 100, P < 0.0001). During a mean follow-up of 16.3 months, 60 patients (26.4%) reached the primary endpoint, a composite of all-cause death, heart transplantation, malignant arrhythmia, and heart failure-related rehospitalization. Of all clinical (ejection fraction, New York Heart Association functional class), laboratory (brain natriuretic peptide), and immunohistological parameters (CyPA, extracellular matrix metalloproteinase inducer, CD68, CD3, major hisocompatibility complex II, and virus genome) tested, only CyPA was identified as an independent predictor for the composite endpoint [hazard ratio (HR) 2.4; 95% confidence interval (CI) 1.2-5.2; P = 0.019] as well as for all-cause death and heart transplantation alone (HR 4.7; 95% CI 1.1-19.8; P = 0.036). Subgroup analysis revealed CyPA as a predictor in patients with non-inflammatory cardiomyopathy for the composite endpoint (HR 3.0; 95% CI 1.3-6.6; P = 0.007) as well as all-cause death or heart transplantation alone (HR 6.4; 95% CI 1.4-28.1; P = 0.014). CONCLUSIONS: CyPA is an independent predictor of clinical outcome in patients with congestive heart failure undergoing endomyocardial biopsy.
AIMS: Cyclophilin A (CyPA) represents a ubiquitous intracellular protein, which is secreted by inflammatory and by dying/necrotic cells. The aim of this study was to evaluate the prognostic relevance of CyPA expression in endomyocardial biopsies of consecutive patients with congestive heart failure. METHODS AND RESULTS: A total of 227 unselected patients (age 53.9 ± 15 years) with congestive heart failure undergoing endomyocardial biopsy for diagnostic reasons were enrolled. Biopsies were analysed using established histopathological and immunohistological criteria together with CyPA staining. Virus genome was studied by polymerase chain reaction. CyPA was significantly enhanced in patients with inflammatory cardiomyopathy (n = 127) as compared with patients with non-inflammatory cardiomyopathy (n = 100, P < 0.0001). During a mean follow-up of 16.3 months, 60 patients (26.4%) reached the primary endpoint, a composite of all-cause death, heart transplantation, malignant arrhythmia, and heart failure-related rehospitalization. Of all clinical (ejection fraction, New York Heart Association functional class), laboratory (brain natriuretic peptide), and immunohistological parameters (CyPA, extracellular matrix metalloproteinase inducer, CD68, CD3, major hisocompatibility complex II, and virus genome) tested, only CyPA was identified as an independent predictor for the composite endpoint [hazard ratio (HR) 2.4; 95% confidence interval (CI) 1.2-5.2; P = 0.019] as well as for all-cause death and heart transplantation alone (HR 4.7; 95% CI 1.1-19.8; P = 0.036). Subgroup analysis revealed CyPA as a predictor in patients with non-inflammatory cardiomyopathy for the composite endpoint (HR 3.0; 95% CI 1.3-6.6; P = 0.007) as well as all-cause death or heart transplantation alone (HR 6.4; 95% CI 1.4-28.1; P = 0.014). CONCLUSIONS:CyPA is an independent predictor of clinical outcome in patients with congestive heart failure undergoing endomyocardial biopsy.
Authors: Christine S Zuern; Britta Walker; Martina Sauter; Malte Schaub; Madhumita Chatterjee; Karin Mueller; Dominik Rath; Sebastian Vogel; Roland Tegtmeyer; Peter Seizer; Tobias Geisler; Reinhard Kandolf; Florian Lang; Karin Klingel; Meinrad Gawaz; Oliver Borst Journal: Clin Res Cardiol Date: 2015-05-26 Impact factor: 5.460
Authors: Xiaoyan Yin; Subha Subramanian; Shih-Jen Hwang; Christopher J O'Donnell; Caroline S Fox; Paul Courchesne; Pieter Muntendam; Neal Gordon; Aram Adourian; Peter Juhasz; Martin G Larson; Daniel Levy Journal: Arterioscler Thromb Vasc Biol Date: 2014-02-13 Impact factor: 8.311
Authors: Nicola L Diny; Xuezhou Hou; Jobert G Barin; Guobao Chen; Monica V Talor; Julie Schaub; Stuart D Russell; Karin Klingel; Noel R Rose; Daniela Čiháková Journal: Eur J Immunol Date: 2016-10-25 Impact factor: 5.532
Authors: David Heinzmann; Anna Bangert; Anna-Maria Müller; Saskia N I von Ungern-Sternberg; Frederic Emschermann; Tanja Schönberger; Madhumita Chatterjee; Andreas F Mack; Karin Klingel; Reinhard Kandolf; Miroslav Malesevic; Oliver Borst; Meinrad Gawaz; Harald F Langer; Hugo Katus; Gunter Fischer; Andreas E May; Ziya Kaya; Peter Seizer Journal: PLoS One Date: 2015-04-20 Impact factor: 3.240
Authors: Karin A L Mueller; Iris I Mueller; David Eppler; Christine S Zuern; Peter Seizer; Ulrich Kramer; Ina Koetter; Martin Roecken; Reinhard Kandolf; Meinrad Gawaz; Tobias Geisler; Joerg C Henes; Karin Klingel Journal: PLoS One Date: 2015-05-12 Impact factor: 3.240
Authors: Xuezhou Hou; Guobao Chen; William Bracamonte-Baran; Hee Sun Choi; Nicola L Diny; Jungeun Sung; David Hughes; Taejoon Won; Megan Kay Wood; Monica V Talor; David Joel Hackam; Karin Klingel; Giovanni Davogustto; Heinrich Taegtmeyer; Isabelle Coppens; Jobert G Barin; Daniela Čiháková Journal: Cell Rep Date: 2019-07-02 Impact factor: 9.423
Authors: Karin A L Mueller; Johannes Patzelt; Manuela Sauter; Philipp Maier; Sarah Gekeler; Karin Klingel; Reinhard Kandolf; Peter Seizer; Meinrad Gawaz; Tobias Geisler; Harald F Langer Journal: ESC Heart Fail Date: 2018-08-31